If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 10 of 10
Phase II, Single-Arm, Open-Label, Multicenter Study Evaluating the Efficacy of Adjunctive Zanubrutinib and CAR T-Cell Therapy in Aggressive B-cell Non-Hodgkins Lymphoma
Phase II Study Evaluating Adjunctive Zanubrutinib and CAR T-cell therapy in Aggressive B-cell Non-Hodgkins Lymphoma
Protocol No
NU-20H09-NHL
Categories
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma
To find out if this approach is better or worse than the usual approach for DLBCL patients receiving CAR T-cell therapy. The usual approach for Relapsed/Refractory DLBCL patients is follow-up visits with no further therapy.
Protocol No
SWOG-S2114
Categories
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Protocol No
TENEOBIO-TENEOTWO-TNB486-001
A Multi-Center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B
Phase II MB-CART2019.1 for R/R DLBCL
Protocol No
MILTENYI-MB-CART2019-1-DLBCL
Categories
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell NHL
Protocol No
CARIBOU-CB10A-ANTLER-NHL
Categories
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Loncastuximab Tesirine with Rituximab vs Immunochemotherapy in DLBCL
Protocol No
ADCT-402-311-DLBCL
Categories
A Multicenter Phase 1, Open-Label Trial of Loncastuximab Tesirine in Combination with DA-EPOCH-R in Patients with Previously Untreated Aggressive B-cell Lymphoid Malignancies
A Phase 1 Trial of Tesirine in Patients with B-cell Lymphoid Malignancies
Protocol No
IIT-HAMADANI-ADCT-LONCA
Categories
A Randomized Phase III Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma
Trial of Zanubrutinib in older patients with mantle cell lymphoma
Protocol No
ALLIANCE-A052101
Categories
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Protocol No
C4THERAPEUTICS-CFT7455-1101
Categories
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Compl
Rituximab with or without SCT in Treating Pt with MRD-Neg MCL in First Complete Remission
Protocol No
ECOG-EA4151
Categories